CAPRICOR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.83 USD | +2.33% |
|
+4.09% | -1.23% |
| Jul. 01 | Capricor Therapeutics Joins Russell 3000, Russell 2000 Indexes | MT |
| Jul. 01 | Capricor Therapeutics, Inc.(NasdaqCM:CAPR) added to Russell 2000 Dynamic Index | CI |
Financials (USD)
| Sales 2024 * | 22.24M | Sales 2025 * | 48.5M | Capitalization | 154M |
|---|---|---|---|---|---|
| Net income 2024 * | -38M | Net income 2025 * | -29M | EV / Sales 2024 * | 6.94 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.18 x |
| P/E ratio 2024 * |
-4.1
x | P/E ratio 2025 * |
-5.49
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Capricor Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.33% | ||
| 1 week | +4.09% | ||
| Current month | +1.26% | ||
| 1 month | -14.96% | ||
| 3 months | -29.90% | ||
| 6 months | -5.66% | ||
| Current year | -1.23% |
1 week
4.56
5.25
1 month
4.456.15
Current year
3.567.28
1 year
2.688.22
3 years
2.568.22
5 years
0.8812.32
10 years
0.88106.80
| Managers | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 4.83 | +2.33% | 282,578 |
| 24-07-02 | 4.72 | -2.48% | 229,516 |
| 24-07-01 | 4.84 | +1.47% | 642,734 |
| 24-06-28 | 4.77 | +2.80% | 4,272,056 |
| 24-06-27 | 4.64 | +0.22% | 330,550 |
Delayed Quote Nasdaq, July 03, 2024 at 01:00 pm EDT
More quotes
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.83
USD
Average target price
19.8
USD
Spread / Average Target
+309.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.23% | 151M | |
| +15.58% | 122B | |
| +16.60% | 113B | |
| +17.55% | 26.22B | |
| -24.33% | 19.01B | |
| -19.14% | 15.71B | |
| -17.95% | 15.22B | |
| -46.81% | 14.72B | |
| +58.78% | 14.58B | |
| +4.91% | 13.84B |
- Stock Market
- Equities
- CAPR Stock
